Targeting diverse clinical challenges in rheumatic immune differential testing, DIA-UP launches the triple biomarker master plate covering RF, ASO and CCP. Optimized for batch consistency, metrological traceability, third-party quality control compatibility and analytical performance, the product meets dual demands of large-scale kit manufacturing for reagent manufacturers and high-volume testing in hospitals at all tiers:

Specialized process calibration for the combined RF/ASO/CCP system minimizes intra-batch and inter-batch deviation. Stability is verified across more than 10 mass-production batches each year, delivering consistent results for repeat testing of challenging specimens and high-throughput runs, with tightly controlled long-term production quality fluctuation.

With an annual output of 10 million test dosages, all test results are traceable to standardized chemiluminescence platforms with complete, compliant metrological documentation, supporting manufacturers’ IVD kit registration and quality control filing.

Custom dedicated calibration schemes enable seamless compatibility with mainstream third-party quality control products including Bio-Rad and Randox. Laboratories can conveniently conduct internal quality control and external quality assessment, drastically cutting manufacturers’ R&D costs for supporting QC reagents.

Optimized antigen-antibody pairs and immune reaction systems enhance detection capability at low CCP concentration ranges, capturing trace autoantibody signals to significantly reduce missed detection of early RA and occult rheumatic lesions, ideal for large-scale primary screening.

Extended linear detection intervals for RF, ASO and CCP effectively suppress response bias at high analyte concentrations. Accurate, stable readings are delivered for both low-concentration mild specimens and high-value samples from active severe cases, fully covering the specimen spectrum of all rheumatic autoimmune patients.